Cargando…
Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn’s disease
INTRODUCTION: Crohn’s disease (CD) is a chronic inflammatory bowel disease characterized by a relapsing/remitting course with transmural inflammation of potentially any section of the digestive tract. Certolizumab pegol (CZP) is a pegylated Fc-free Fab’ fragment of a humanized anti-TNF-alfa monoclon...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012434/ https://www.ncbi.nlm.nih.gov/pubmed/21221187 |